Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?

Alvotech (ALVO) shares rallied 8.6% to $8.7 on notable volume, extending gains following the EMA's CHMP backing its biosimilar regulatory filings for Amgen's Prolia/Xgeva and J&J's Simponi. Despite this momentum, the company projects a 57.9% year-over-year decline in upcoming quarterly EPS to $0.08, alongside an 11% revenue increase to $114.27 million, with the consensus EPS estimate remaining flat for 30 days, which may temper sustained price appreciation. The stock currently holds a Zacks Rank #3 (Hold).

Analysis

Alvotech (ALVO) shares experienced a significant 8.6% rally to $8.70, accompanied by higher-than-average trading volume. This price movement is directly attributable to a positive regulatory catalyst: the European Medicines Agency’s CHMP recommended approval for the company's biosimilar versions of Amgen’s Prolia/Xgeva and Johnson & Johnson’s Simponi. While this is a critical de-risking event for Alvotech's pipeline in Europe, the company's near-term financial outlook presents a conflicting picture. Upcoming quarterly revenue is projected to rise 11% year-over-year to $114.27 million, but this is contrasted by a forecasted 57.9% decline in earnings per share to $0.08. Critically, the consensus EPS estimate has remained unchanged for the last 30 days, suggesting the recent share price appreciation is event-driven and not yet supported by improving fundamental earnings expectations, which can be a headwind for sustained momentum.

Key Decisions for Investors

• Given the disconnect between the positive regulatory news and the projected 57.9% YoY earnings decline, investors should be cautious of chasing the rally and monitor for any upward revisions to analyst EPS estimates.
• The EMA's CHMP backing is a significant validation of the pipeline, but its financial contribution is not yet reflected in guidance; a prudent approach is to wait for the upcoming earnings report for more clarity on the path to profitability.
• Note the increased competitive pressure on Amgen (AMGN) and Johnson & Johnson (JNJ) in Europe due to this biosimilar development, which may warrant a review of holdings in those names.